06/23/2026
In less than 10 years, Eli Lilly and Companyl underwent a legendary turnaround under CEO Dave Ricks, who took the helm in 2017 during a challenging time for the industry. As noted by Bloomberg, Ricks faced what he concedes was a "public-relations nightmare" in a turbulent industry. Fast forward nearly a decade, and the landscape has dramatically changed.
The introduction of Mounjaro, a diabetes treatment, and Zepbound, an obesity shot, significantly transformed the company's fortunes and public image. Today, Lilly stands as the most valuable healthcare corporation globally, achieving a remarkable $1 trillion market capitalization, a milestone shared with only a handful of tech giants.
Discover how Ricks navigated this transformation in the paywall-free link below.
https://www.bloomberg.com/features/2026-eli-lilly-weight-loss-drug-boom/?accessToken=eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJzb3VyY2UiOiJTdWJzY3JpYmVyR2lmdGVkQXJ0aWNsZSIsImlhdCI6MTc4MjIzMDA1MCwiZXhwIjoxNzgyODM0ODUwLCJhcnRpY2xlSWQiOiJUSDFIUUpLR0lGUkgwMCIsImJjb25uZWN0SWQiOiIwNzVGQkM5QjIyRUU0MTRDQjFCM0NFNTU3MDcyMTcxOCJ9.94UWvmGSWoZe5Iv2d1_Pv9agMSI682oGBIDun8lFvRA
Dave Ricks steered the 150-year-old drug giant to a $1 trillion market cap. Can he defeat pharma’s boom and bust cycle?